An open-label study of alefacept plus ultraviolet B light as combination therapy for chronic plaque psoriasis

Journal of the European Academy of Dermatology and Venereology

Volumn 19, Issue 5, 2005, Pages 556-563

  Ortonne, J P ^a   Khemis, A ^a   Koo, Jym ^b   Choi, J ^b  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alefacept; Clinical trial; Psoriasis; Ultraviolet B

Indexed keywords

ALEFACEPT;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PHOTOSENSITIVITY; PHOTOTHERAPY; PHOTOTOXICITY; PRIORITY JOURNAL; PSORIASIS VULGARIS; TREATMENT OUTCOME; ULTRAVIOLET B RADIATION;

EID: 27744495938     PISSN: 09269959     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2005.01247.x     Document Type: Article

References (22)

1. Gottlieb AB, Bos JD. Recombinantly engineered human proteins: transforming the treatment of psoriasis. Clin Immunol 2002; 105: 105-116.
2. Prinz JC. The role of T cells in psoriasis. J Eur Acad Dermatol Venereol 2003; 17: 257-270.
3. Majeau GR, Meier W, Jimmo B, Kioussis D, Hochman PS. Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. Structure/function analysis in vitro and in human CD2 transgenic mice. J Immunol 1994; 152: 2753-2767.
4. Sanders ME, Makgoba MW, Sharrow So et al. Human memory T lymphocytes express increased levels of three cell adhesion molecules (LFA-3, CD2, and LFA-1) and three other molecules (UCHL1, CDw29, and Pgp-1) and have enhanced IFN-γ production. J Immunol 1988; 140: 1401-1407.
5. + T cells is independent of cell activation. Cell Adhes Commun 1999; 7: 267-279.
6. Ellis CN, Krueger GG, for the Alefacept Clinical Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001; 345: 248-255.
7. Ortonne J-P, Lebwohl M, Griffiths CEM. Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis. Eur J Dermatol 2003; 13: 117-123.
8. Gordon KB, Vaishnaw AK, O'Gorman J, Haney J, Menter A, for the Alefacept Clinical Study Group. Treatment of psoriasis with alefacept. Correlation of clinical improvement with reductions of memory T-cell counts. Arch Dermatol 2003; 139: 1563-1570.
9. Krueger GG, Papp KA, Stough DB et al. for the Alefacept Clinical Study Group. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002; 47: 821-833.
10. Gordon KB, Langley RG. Remittive effects of intramuscular alefacept in psoriasis. J Drugs Dermatol 2003; 2: 624-628.
11. Fischer T. UV-light treatment of psoriasis. Acta Derm Venereol 1976; 56:473-479.
12. Krueger JG. The immunological basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002; 46: 1-23.
13. Krueger JG, Wolfe JT, Nabeya RT et al. Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratinocyte pathology and by selective depletion of intraepidermal T cells. J Exp Med 1995; 182: 2057-2068.
14. Ozawa M, Ferenczi K, Kikuchi T et al. 312-nanometer ultraviolet B light (narrow-band UV) induces apoptosis of T cells within psoriatic lesions. J Exp Med 1999; 189: 711-718.
15. Koo J, Lebwohl M. Duration of remission of psoriasis therapies. J Am Acad Dermatol 1999; 41: 51-59.
16. Van Weelden H, Young E, van der Leun JC. Therapy of psoriasis: comparison of photochemotherapy and several variants of phototherapy. Br J Dermatol 1980; 103: 1-9.
17. Van Weelden H, Baart De La Faille H, Young E, van der Leun JC. Comparison of narrow-band UV-B phototherapy and PUVA photochemotherapy in the treatment of psoriasis. Acta Derm Venereol 1990; 70: 212-215.
18. Pathak MA, Fitzpatrick TB. Preventive treatment of sunburn, dermatoheliosis, and skin cancer with sun-protective agents. In: Fitzpatrick TB, Eisen AZ, Wolff K et al., eds. Dermatology in General Medicine, 4th edn. McGraw-Hill, New York, 1993: 1689-1717.
19. Fredriksson T, Pettersson U. Severe psoriasis: oral therapy with a new retinoid. Dermatologica 1978; 157: 238-244.
20. Lebwohl M, Christophers E, Langley R et al. for the Alefacept Clinical Study Group. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003; 139: 719-727.
21. Coven TR, Burack LH, Gilleaudeau P et al. Narrowband UV-B produces superior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broadband UV-B. Arch Dermatol 1997; 133: 1514-1522.
22. Krutmann J. The treatment of psoriasis: UVB. Dermatologic Ther 1999; 11: 32-36.